Details of the Drug Reposition

General Information of This Drug (ID: DMCXN80)

• Drug Name: Tozorakimab (DMCXN80)
• Drug Type: Monoclonal antibody

Information on Drug Reposition of This Drug

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Chronic obstructive pulmonary disease	DISQCIRF	CA22	Phase 3	[1]
Acute respiratory failure	DIS5KQ5Y	CB41.0	Phase 3	[2]

References

• [1] ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05624450) A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen. U.S.National Institutes of Health.